Nordoxepin, Urine
Nordoxepin (N-desmethyldoxepin) is a member of the class of drugs known as antidepressants, and is the major metabolite of doxepin. The use of tricyclic antidepressants (TCAs) are one of the primary ways to treat clinical depression. Nordoxepin is one of the first generation of antidepressants.
Nordoxepin, which is the major metabolite of doxepin, has similar biological activity as doxepin. Like the parent drug, the half-life of nordoxepin is between 9-25 hours.
The effects associated with nordoxepin abuse include hallucinations, tachycardia, seizures, nausea, vomiting, tremors, and coma when taken to excess.
- Therapeutic monitoring
- Drug abuse evaluation
- Toxicity assessment
- Patient Compliance
Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.
Serum specimens that are collected in a non-gel red top tube are the preferred specimens of choice. Specimens should be spun and the serum separated and refrigerated.
Stability
- Ambient: 3-5 days
- Refrigeration: 5-7 days
- Frozen: 30 days
- Antidepressant DEA Drug Fact Sheet L
- evine B (ed). Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press. Chapter 14, Therapeutic Drugs II: Antidepressants, pp. 403-420; 2013.
- Balant-Gorgia A.E., Balant LP. Therapeutic drug monitoring of antidepressants. Clin Thera, 1992;14(4):612-4.
- Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
- Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
- Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
- Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996.
- Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
- Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.